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Novel inhibitors are needed to counteract the rapid
emergence of drug-resistant HIV variants. HIV-1
reverse transcriptase (RT) has both DNA polymerase
and RNase H (RNH) enzymatic activities, but
approved drugs that inhibit RT target the poly-
merase. Inhibitors that act against new targets,
such as RNH, should be effective against all of the
current drug-resistant variants. Here, we present
2.80 A˚ and 2.04 A˚ resolution crystal structures of an
RNH inhibitor, b-thujaplicinol, bound at the RNH
active site of both HIV-1 RT and an isolated RNH
domain. b-thujaplicinol chelates two divalent metal
ions at the RNH active site. We provide biochemical
evidence that b-thujaplicinol is a slow-binding RNH
inhibitor with noncompetitive kinetics and suggest
that it forms a tropylium ion that interacts favorably
with RT and the RNA:DNA substrate.
INTRODUCTION
HIV-1 reverse transcriptase (RT) is a key target of anti-AIDS
drugs. RT converts the single-stranded viral genomic RNA into
double-stranded (ds) DNA that is subsequently integrated
into the genome of the host cell. RT has two enzymatic activities
that cooperate to carry out this synthesis: (1) A DNA polymerase
that can use either RNA or DNA as a template, and (2) RNase H
(RNH). Like many other DNA polymerases, RT requires both
a template and a primer; the primer for the first (or ‘‘minus’’)
strand DNA is tRNA lys3. Synthesis of the minus strand DNA
generates an RNA:DNA duplex that is a substrate for RNH;
RNH degrades the viral RNA, leaving a purine-rich segment of
the viral RNA (the polypurine tract, or PPT), which serves as
the primer for the second (or ‘‘plus’’) strand of viral DNA. After
plus strand DNA synthesis copies the first 18 nucleotides of
the minus strand, RNH removes the tRNA primer. The poly-
merase and RNH activities are both required for viral replication;
the RNH activity of RT cannot be replaced by endogenous
cellular RNases H (Tisdale et al., 1991; Schatz et al., 1990).Structure 17, 1625–1RT is composed of a 66 kDa (p66) and a 51 kDa (p51) subunit
(Figure 1), which derive, by cleavage by the viral protease, from
the Gag-Pol polyprotein precursor. The first 440 residues of p66
and p51 are identical. In both subunits, these residues comprise
the four polymerase subdomains: thumb, palm, fingers, and
connection (Kohlstaedt et al., 1992; Jacobo-Molina et al.,
1993). The RNH domain is formed by the C-terminal residues
427–560 of p66 (Kohlstaedt et al., 1992; Jacobo-Molina et al.,
1993; Huang et al., 1998; Sarafianos et al., 2001). The individual
subdomains in p51 and p66 have similar structures but are
arranged differently. Amino acid residues directly responsible
for both enzymatic activities reside entirely within the p66
subunit, whereas the p51 subunit is believed to play a more
structural role. The p66 subunit can be in an ‘‘open’’ conforma-
tion, in which the thumb rotates away from the fingers to form
a large cleft that accommodates double-stranded nucleic acid
substrates. Conversely, in the absence of nucleic acid, the
p66 subunit assumes a ‘‘closed’’ conformation, in which the
thumb rotates toward the fingers to fill much of this cleft (Hsiou
et al., 1996).
The RT inhibitors used to treat HIV-1 infections are typically
given to patients as part of a cocktail of therapeutic agents in
a treatment strategy known as highly active antiretroviral therapy
(HAART). However, the efficacy of these therapies is limited by
the emergence of drug-resistant variants of the virus (reviewed
in Sarafianos et al., 2004). To address this problem, new inhibi-
tors must be developed that can block the replication of the
existing drug-resistant viruses. This means that new inhibitors
that act against the same targets as the existing drugs must be
relatively effective against the extant resistant viruses, or the
new inhibitors can inhibit essential viral functions that are not
blocked by existing drugs. To date, all of the RT inhibitors that
have been approved for clinical use target the polymerase
activity of RT, not its RNH activity. Given that RNH activity is
essential for viral replication (Tisdale et al., 1991; Schatz et al.,
1990), RNH inhibitors (RNHIs) have considerable potential as
anti-AIDS therapeutics.
One problem in developing an RNHI active site inhibitor is the
absence of a deep pocket into which the inhibitors can bind
(Davies et al., 1991). However, it should be possible to use the
active site metal ions as anchor points for inhibitor binding.
A diketo acid inhibitor (Shaw-Reid et al., 2003) was shown to635, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1625
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HIV Reverse Transcriptase-RNase H/b-Thujaplicinolbind in ametal-dependent manner to the RNH domain of RT. The
authors postulated that this RNHI has a metal ion–dependent
inhibition mechanism that is similar to that of related HIV inte-
grase inhibitors (Grobler et al., 2002). N-hydroxyimide inhibitors
were designed to chelate the active site magnesium ions of the
RNH domain, on the basis of a specific interaction with the two
metal ions (Klumpp et al., 2003). These inhibitors bind directly
to the RNH domain; there is no binding in the absence of metal
ions. Budihas et al. (2005) have presented compelling evidence
that b-thujaplicinol (2,7-dihydroxy-4-(propan-2-yl)-cyclohepta-
2,4,6-trien-1-one), a natural product from Western red cedar
(Gardner et al., 1957), inhibits RNH activity. They proposed
that b-thujaplicinol chelates the active site metal ions at the
RNH active site (Budihas et al., 2005). A structure has previously
been reported showing an RNHI, DHBNH, bound near the RT
polymerase active site, more than 50 A˚ from the RNase H active
site (Himmel et al., 2006), and a structure for an active, isolated
HIV-RNH domain in a complex with an N-hydroxyimide inhibitor
has been briefly described (Klumpp and Mirzadegan, 2006), but
no full-length RT coordinates have yet been published in which
an RNHI is in complex with the RNH domain. We present
here a structure of HIV-1 RT at 2.80 A˚ resolution and a structure
of the isolated RNH domain of HIV-1 RT (isoRNH) at 2.04 A˚ reso-
lution, each in a complex with b-thujaplicinol. These structures
reveal the details of the interactions of the RNHI and RNH,
including the coordination of the two catalytic metal ions.
RESULTS
Binding and Inhibitory Properties of b-Thujaplicinol
It has previously been reported that b-thujaplicinol inhibits the
RNH activity of HIV-1 with an IC50 of 0.21 mM in a manner that
is not competitive with the nucleic acid substrate (Budihas
et al., 2005). We find that b-thujaplicinol is a time-dependent
Figure 1. Overview of RT Structure
An RT ribbon diagram of the RT/b-thujaplicinol
structure is shown. The subdomains of the p66
subunit (including the RNase H domain) are
colored as follows: fingers, blue; palm, red; thumb,
green; connection, yellow; RNH, orange; and the
p51 subunit, gray. b-thujaplicinol is shown space-
filled in magenta and red.
Figure 2. Inhibition of HIV-1 RT RNH Activity by b-Thujaplicinol
(A) Progress curves describing cleavage by RNH in the presence of-0,: 30,
; 45,A60, d 110, + 200, j 400, and x 600 nM b-thujaplicinol. Progress curves
were fit as described in Experimental Procedures.
(B) Kobs versus b-thujaplicinol concentration. Data plotted are the average of
three measurements ± SD.
(C) Progress curves describing cleavage by RNH in the presence of 100 nM
b-thujaplicinol and various concentrations of substrate (,10, D20, V30,
>40,B60,-80,:100,;120,A140, d1ff70, x210, and +300 nM).
(D) Plot of Kobs as a function of substrate concentration. Data are the average
of duplicates ± SD (error bars). All data shown are representative examples of
greater than three independent experiments.
inhibitor of the RNH that displays
noncompetitive kinetics (Figure 2). The
inhibitor does not affect the polymerase
activity of RT (data not shown). b-thujapli-
cinol is also an inhibitor of the isolated
RNase H domain. This inhibition is
noncompetitive in steady-state experi-
ments (data not shown). To evaluate the
mechanism of the time dependence,
kobs was determined for RT by fitting
the progress curves as described in
Experimental Procedures. The relation-
ship between kobs and b-thujaplicinol
concentration was linear (Figure 2B), sug-
gesting simple reversible inhibition. Ki
app
was estimated from Figure 2B to be 0.14 mM. Progress curves
generated at multiple substrate concentrations revealed no
significant dependence of kobs on substrate concentration,
consistent with noncompetitive inhibition (Figures 2C and 2D).
Direct binding studies performed using both surface plasmon
resonance (SPR) and intrinsic protein fluorescence revealed1626 Structure 17, 1625–1635, December 9, 2009 ª2009 Elsevier Ltd All rights reserved
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HIV Reverse Transcriptase-RNase H/b-Thujaplicinolthat b-thujaplicinol has relatively weak binding affinity for the
free enzyme (KD
SPR = 6 mM; KD
fluor = 0.73 mM; Table 1; Figure 3).
Binding studies were also performed in the presence of a nonhy-
drolyzable dsRNA substrate analog using intrinsic protein
fluorescence. The presence of a substrate analog significantly
decreased the KD value (KD
fluor = 0.185 mM; Table 1; Figure 3),
which is consistent with the Ki
app generated by kinetic studies.
These data suggest that the presence of a bound RNA:DNA
substrate is necessary to achieve maximal binding of b-thujapli-
cinol to RT. The time dependence of inhibition may be because
assembly of the enzyme-inhibitor-substrate ternary complex is
slow relative to enzyme turnover. The increased binding affinity
of b-thujaplicinol in the presence of a substrate could be the
result of a positive interaction between the substrate and
the bound inhibitor. Alternatively, there could be a decrease in
the dissociation rate constant for the inhibitor as a result of steric
occlusion following substrate binding. SPR studies confirmed
Table 1. Equilibrium Binding Constants for Binding of
b-Thujaplicinol to HIV-1 RT
Binding Condition KD
fluor (mM)a KD
SPR (mM)b Ki
app (mM)c
Enzyme, no metal — >100 —
Enzyme + MgCl2 0.73 ± 0.09 6 ± 1 —
Enzyme + MgCl2 +
dsRNA
0.185 ± 0.008 — —
Enzyme + MgCl2 +
RNA:DNA hybrid
— — 0.14 ± 0.03
All numbers represent the average of at least 2 independent experiments.
a KD
fluor are equilibrium binding constants determined by quenching the
intrinsic protein fluorescence of RT. See Figure 3.
bKD
SPR are equilibrium binding constants determined by surface plas-
mon resonance. See Figure 3.
c Ki
app is the Ki value determined kinetically. See Figure 2.Structure 17, 1625–16that there was no detectable inhibitor binding (IC50 > > 100 mM,
data not shown) in the absence of divalent metal ions.
Overall Protein Conformations
The RT69A HIV-1 RT (Bauman et al., 2008) that was used to
generate the complex with b-thujaplicinol crystallized with the
symmetry of space group C2 (Table 2) with one protein molecule
per asymmetric unit, and the protein was in a closed conforma-
tion typical of unliganded (no bound nucleic acid or inhibitor) RT.
The isolated RNH domain crystallized in space group P31, with
two protein molecules per asymmetric unit. The structures of
the RNH domain in the intact RT and the isolated RNH domain
corresponded closely to previously published RT structures.
Although the last helix of the p66 subunit (helix E0, secondary
structure labeled as in Jacobo-Molina et al., 1993) was partially
unwound in some of the previously reported structures, we
found helix E0 intact and well-ordered in both of the structures
described here.
Our two structures, which were determined and refined inde-
pendently, from different starting models, showed good overall
agreement. When all main chain atoms of each of the isolated
RNH copies in the asymmetric unit were superimposed on those
of RT, we calculated a root mean square difference of 0.54 to
0.55 A˚ between corresponding main chain atoms and 1.63 to
1.66 A˚ between side chain atoms. The agreement between the
atoms of active site residues (Asp443, Glu478, Asp498,
His539, and Asp549) was even better, with an rms difference
of 0.29 to 0.36 A˚ between main chain atoms, 1.01 to 1.02 A˚
between side chain atoms, 0.56 to 0.58 A˚ between inhibitor
atoms, and 0.17 to 0.27 A˚ between corresponding Mn2+ atoms.
b-Thujaplicinol Binds at the RNH Active Site
The binding of the inhibitor is essentially identical in both the RT
and isolated RNH structures (Figures 4 and 5). Both structuresFigure 3. Binding of b-Thujaplicinol to
HIV-1 RT
(A) Surface plasmon resonance sensorgrams of
increasing concentrations of b-thujaplicinol inter-
acting with RT in the absence of substrate.
(B) Binding isotherm from A.
(C) Intrinsic protein fluorescence quenching as
a result of incubation with increasing concentra-
tions of b-thujaplicinol in the presence of a dsRNA
substrate analog.
(D) Example binding isotherm describing rfu max
as a function of b-thujaplicinol concentration
in the presence of a nonhydrolyzable substrate
analog consisting of dsRNA. Data shown are
representative examples of at least two indepen-
dent examples.35, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1627
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HIV Reverse Transcriptase-RNase H/b-Thujaplicinolexhibited strong difference Fourier (Fo-Fc) electron density peaks
for two manganese ions at the RNH active site (Figure 4), sepa-
rated by a distance of about 3.8 A˚. We designate these manga-
nese ions ‘‘A’’ and ‘‘B’’ following the convention for a two-cation
mechanism, which is discussed below. Glu478 and Asp 498
coordinate metal ion B, and Asp549 coordinates metal ion A
(Figure 6). The side chain of Asp443 is between the Mn2+ ions
and coordinates both metals. In both structures, b-thujaplicinol
coordinates the two Mn2+ ions and forms ionic or hydrogen-
bond interactions with the side chains of residues Glu478,
Asp498, His539, and Asp549 (Figures 5 and 6). All three oxygen
atoms of the tropolone ring of b-thujaplicinol coordinate the
manganese ions. Themiddle oxygen (at the 1-position) of the tro-
polone ring coordinates both manganese ions. Metal ion A is
coordinated by four ligands in both of the structures, including
the 2-hydroxyl on the tropolone ring. Metal ion B, however, is
coordinated by six or seven ligands (in vivo, where the cation is
magnesium, six-atom-coordination is expected). The isolated
RNH structure shows that there is an ionic or hydrogen-bond
contact between one of the inhibitor hydroxyls and the side chain
of Arg557. Arg557 is not present in the full-length RT crystallized
here. In the isolated RNH structure, Arg557 also forms a salt
Table 2. Data Collection and Refinement Statistics
Statistic RT isoRNH
PDB ID Code 3IG1 3K2P
Data Collection
Resolution Range (A˚) 35–2.80 50–2.04
Rsym (%) 6.1 4.8
Average I/s 15.3 23.7
Completeness (%) 94.3 99.8
Unique Reflections/Multiplicity 28769/2.7 20314/3.4
Refinement
Sigma Cutoff 0.0 0.0
Resolution Range Used (A˚) 33.8–2.80 44.3–2.04
Completeness in Range (%) 91.9 99.1
R-factor/Rfree(%) 23.8/25.5 21.1/25.4
Cross-Validated Coordinate Error (A˚)a 0.45 0.179
No. of Protein/Solvent Atoms 7875/74 2045/219
No. of Inhibitor/Cation Atoms 13/2 13/2
Average B-factors (A˚2)
Protein/Solvent 89.3/58.6 34.0/45.0
Inhibitor/cations 104.2/65.7 38.19/31.88
RMS Bond Lengths (A˚)/Angles ()b 0.008/1.70 0.022/1.99
Ramachandran Regions
Most favored 95.1% 93.4%
Additional Allowed 4.8% 6.1%
Generous or disallowed 0.1% 0.4%
For RT, unit cell and space group values are as follows: 164.1, 71.3,
108.5 A˚, 90.0, 105.1, 90.0, and C2. For isoRNH, unit cell and space
group values are as follows: 51.1, 41.1, 112.4, 90.0, 90.0, 120.0,
and P31.
a See Kleywegt and Bru¨nger, 1996; Kleywegt et al., 1994; and Luzzati,
1952.
b See Engh and Huber, 1991.1628 Structure 17, 1625–1635, December 9, 2009 ª2009 Elsevier Ltdbridge with Asp549. Ala538 has a 4 A˚ nonpolar interaction with
the tropolone ring.
DISCUSSION
Tropylium Chemistry and Mn2+ Coordination
A tropylium ion is a seven-membered aromatic ring, containing
three conjugated double bonds and an overall +1 charge (for
reviews, see (Pietra, 1973; Bertelli, 1973; and Kolomnikova and
Parnes, 1967); Figure 6, inset). If one of the carbon atoms is
changed to a carbonyl, the ring is called a tropolone, and the
ring retains some aromatic character (Dewar, 1945). b-Thujapli-
cinol is a member of the thujaplicin family of compounds, which
are characterized by a tropolone ring and an acidic hydroxyl
(for review, see Pauson, 1955). On the basis of the properties
of tropolones, b-thujaplicinol might be expected to carry at least
a partial positive charge on its tropolone ring and have a corre-
sponding partial negative charge shared by resonance involving
its carbonyl and hydroxyls (Figure 6, inset).
RNH Enzymatic Mechanism
For over a decade, the enzymatic mechanism of HIV RNH and
related RNases has been the subject of debate, with several
hypotheses being advanced. All of the proposed mechanisms
suggest that cleavage of substrate likely occurs by general
base catalysis in which an activated water molecule, acting as
a Lewis base, makes a nucleophilic attack on a phosphate of
the RNA strand. This scissile phosphate becomes a good leaving
group when the product is reprotonated by general acid catal-
ysis. In Escherichia coli RNase HI, it has been suggested that
His124 (RT His539) serves as the general base (Oda et al.,
1993). The hypotheses diverge onwhether one cation (Nakamura
et al., 1991; Oda et al., 1991; Katayanagi et al., 1993; Kanaya
et al., 1996) or two cations (Yang et al., 1990; Steitz and Steitz,
1993) are required for catalysis, and it has also been proposed
that the second cation (when present) serves to attenuate catal-
ysis (Keck et al., 1998;Goedken andMarqusee, 2001). In the two-
cation mechanism, Metal A helps to position the catalytic water
for nucleophilic attack, and Metal B stabilizes the pentacovalent
transition state of reaction (Yang et al., 1990; Steitz and Steitz,
1993). Recently published structures of Bacillus halodurans
RNase H/RNA:DNA (Nowotny et al., 2005) and human RNase
H1/RNA:DNA (Nowotny et al., 2007), bothwith an active site point
mutation to inactivate the enzyme, show the substrate bound to
the active site in position appropriate for cleavage along with
two cations, lending support to the two-cation mechanism.
Mechanism of Inhibition
The presence of a carbonyl and at least one hydroxyl on the tro-
polone ring of the thujaplicins gives this class of compounds the
ability to chelate metal cations, and a-thujaplicin weakly inhibits
(IC50 50 mM) HIV RNase H, suggesting that this compound coor-
dinates one of the RNH active site cations (Budihas et al., 2005).
The structures reported in the present study show that the addi-
tional hydroxyl of b-thujaplicinol at the 7-position of the tropolone
ring (Figure 6) allows this compound to coordinate both divalent
cations.
To investigate the mechanism of inhibition, a structure for
human RNase H1 (PDB code 2QKK; Nowotny et al., 2007) wasAll rights reserved
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HIV Reverse Transcriptase-RNase H/b-Thujaplicinolsuperimposed on our current RT/b-thujaplicinol structure (super-
position was based on p66 residues Val442 to Gly444 focusing
on Asp443, which coordinates both cations). The human RNase
H1 is in a complex with an RNA:DNA substrate appropriately
positioned for cleavage; catalysis is prevented by a point muta-
tion, Asp210Asn, which is at a position equivalent to RT residue
Asp498 (Nowotny et al., 2007). The active sites of the two
structures superimpose well, including the two RNase H1 Ca2+
ions in the structure of the human enzyme that occupy virtually
the same positions as the Mn2+ ions of the two RNH structures
reported here (Figure 7). This superposition suggests that
b-thujaplicinol usurps the position of both the scissile phos-
phate and the water believed to serve as the nucleophile during
catalysis.
The kinetic analysis reported here (Figure 2) supports the view
that b-thujaplicinol is a noncompetitive inhibitor, suggesting that
the RNA:DNA substrate and b-thujaplicinol can be bound to the
enzyme together, forming an Enzyme$Substrate$Inhibitor (E$S$I)
complex. A recently published paper describes the inhibition of
RT by b-thujaplicinol under pre-steady state conditions (Beil-
hartz et al., 2009). In this experiment, the authors pre-form the
Enzyme$Substrate (E$S) complex and show that b-thujaplicinol
is unable to inhibit RNase H cleavage. In a separate experiment,
the authors demonstrate that b-thujaplicinol is not an inhibitor of
polymerase-dependent cleavage. Both experiments provide
compelling evidence that, when bound, the RNA:DNA substrate
blocks access to the RNaseH active site. However, these experi-
Figure 4. Electron Density at the Binding
Site
For RT/b-thujaplicinol (A) and the isolated RNH
domain in complex with b-thujaplicinol (B), three
electron density maps are shown in ‘‘wall-eyed’’
stereo: a 2Fo-Fc difference map (cyan), contoured
at 1 sigma; a simulated-annealing Fo-Fc omit map
in which b-thujaplicinol and both manganese
cations were omitted (magenta), contoured at
3.5 sigma in (A) and 2.5 sigma in (B); and a simu-
lated-annealing Fo-Fc omit map in which only the
cations were omitted (dark green), contoured at
9.5 sigma.
ments do not provide information as to
whether the substrate is able to bind to
the Enzyme$Inhibitor (E$I) complex. An
inhibitor that is able to bind only the free
enzyme, and not the E$S complex, can
still demonstrate noncompetitive kinetics
if the substrate is able to bind the E$I
complex thereby forming the E$S$I
complex. Noncompetitive kinetics have
been shown in other enzyme systems
(Krishnaswamy, 2005; Wittwer et al.,
2007), where a small molecule is known
to bind at the active site but is insufficient
to displace the macromolecular sub-
strate. In these cases, the inhibitor is
able to block access to the active site
but does not block the ability of the
substrate to bind to the enzyme through interactions at regions
beyond the active site. Given that the RNA:DNA substrate inter-
acts with RT over a large region extending from the polymerase
active site to the RNH active site (Ding et al., 1997), it is reason-
able to propose that the RNA:DNA substrate can be bound to
RT/b-thujaplicinol even as the inhibitor competes with the RNA
strand for access to the RNH active site.
We have previously shown that an RNA:DNA substrate can
bind to RT without engaging the RNH active site. In a structure
of RT complexed with an RNA:DNA substrate containing a
polypurine tract (PDB code: 1HYS) (Sarafianos et al., 2001),
the polypurine tract of the RNA strand interacts with the RNase
H domain but is not cleaved because the scissile phosphate is
about 4 A˚ away from the active site (Sarafianos et al., 2001).
To model what might happen when RT/b-thujaplicinol binds an
RNA:DNA substrate, the aforementioned RT/RNA:DNA structure
(PDB code: 1HYS) was superposed on our RT/b-thujaplicinol
structure (the superposition was based on residues Val442 to
Asp443, Glu 478, and Asp549). This superposition suggests
that the two nonbridging oxygen atoms of the scissile phosphate
could form ionic interactions with the positively charged tropo-
lone ring of b-thujaplicinol (Figure 8). As stated above, binding
studies using both SPR and intrinsic protein fluorescence
showed a significant increase in the affinity of RT for b-thujaplici-
nol when a double-stranded nucleic acid substrate analog was
present (Table 1). The increase in affinity of b-thujaplicinol for
RT in the presence of substrate could be the result of directStructure 17, 1625–1635, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1629
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HIV Reverse Transcriptase-RNase H/b-Thujaplicinolfavorable interactions between the inhibitor and substrate in the
ternary complex. Alternatively, the increased affinity could be
caused by a decrease in the off-rate if the bound substrate
interfered with the release of the inhibitor from the complex. In
this case, the on-rate for the inhibitor would also be reduced
in the enzyme-substrate complex relative to the free enzyme
complex. b-thujaplicinol would be expected to bind preferen-
tially to the free enzyme. Subsequent binding of substrate would
then trap the E$S$I complex. This could explain the time-depen-
dent nature of the inhibition if dissociation of the E$S complex is
slow relative to both the formation of the E$I complex and turn-
over of the E$S complex. Interestingly, inhibition of the isolated
RNase H domain by b-thujaplicinol is not time dependent. In
this case, the binding affinity of the RNA:DNA substrate is signif-
icantly weaker, and turnover of the E$S complex is significantly
slower. If association and dissociation of b-thujaplicinol are
hindered by the presence of nucleic acid substrate, as sug-
gested by these studies, this might partly explain why potent
in vitro inhibition of RNH activity has not yet been translated
into potent in vivo antiviral activity. The processive nature of
the RT polymerase could limit the presence of free RT available
for binding by active site RNHIs. However, polymerase-indepen-
dent activities of RNH, such as primer removal steps, should still
be sensitive to active site directed RNHIs. Beilhartz et al. (2009)
have shown that b-thujaplicinol inhibits polymerase-indepen-
dent ‘‘secondary cuts’’ in the RNA strand caused by the RNH.
Additional structural and kinetic studies are necessary to fully
Figure 5. Superposition of the Binding Sites in the Two RNH
Structures
Residues Val442 to Asp443, Glu 478, and Asp549 were superimposed for the
coordinates for RT (carbons in yellow) and the isolated RNH domain (carbons
in black). The coordinates of the two structures, which were refined indepen-
dently, agree remarkably well with each other. Manganese cations are labeled
A and B according to the convention used in the previously proposed two-
cation mechanism (Yang et al., 1990; Steitz and Steitz, 1993).1630 Structure 17, 1625–1635, December 9, 2009 ª2009 Elsevier Ltdunderstand the interactions of the inhibitor with the RT/RNA:DNA
complex.
A recent model suggests that the tropolone ring of b-thujapli-
cinol forms p-stacking interactions with the side chain of Tyr501,
in addition to coordinating one of the active site divalent cations
(Beilhartz et al., 2009). Furthermore, it was found that sub-
stituting benzoyl-L-phenylalanine, an artificial amino acid, in
place of Tyr501 conferred resistance to inhibition by b-thujaplici-
nol. These results were explained by proposing that the artificial
side chain rotated away from b-thujaplicinol to form more
favorable interactions with other RT residues, depriving b-thuja-
plicinol of p-stacking interactions. Our structural results do not
support this picture. Instead, they indicate that b-thujaplicinol
coordinates both divalent cations at the RNH active site and
is unavailable for interactions with Tyr501. Resistance by
benzoyl-L-phenylalanine may be explained by assuming that
the bulky side chain interferes sterically with the binding of b-thu-
japlicinol but can be displaced by the natural substrate.
Inhibitors containing diketo acid moieties interfere with the
enzymatic activities of both HIV-1 RNH and HIV integrase
(Shaw-Reid et al., 2003; Grobler et al., 2002]. In both cases, it
has been proposed that these inhibitors act by coordinating
two divalent cations at the active site (Grobler et al., 2002). Other
integrase inhibitors have subsequently been developed on the
basis of this hypothesis (Garvey et al., 2008), but no crystal struc-
ture is currently available that shows the interactions between
integrase and these inhibitors. Because the active site of RNH
is structurally similar to those of integrases and transposases
(Richardson et al., 2006), the structures presented here may be
Figure 6. Contact Distances Between Protein, Cations, and Inhibitor
Electrostatic (red) and several hydrophobic (gray) interactions are indicated
with distances in A˚. Solid lines designate coordination of manganese cations
A and B, whereas dashed lines indicate direct protein-inhibitor interactions.
Inset: A diagram of the tropylium ion charge distribution and its application
to b-thujaplicinol.All rights reserved
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of integrase with its inhibitors.
Conclusions
We have presented a 2.80 A˚ resolution structure of HIV-1 RT and
a 2.04 A˚ structure of the isolated RNH domain, both with b-thu-
japlicinol bound in virtually identical modes at the RNH active
site. Although a conclusive picture of protein-inhibitor-substrate
interactions will require a structure of RT in complex with both
an RNA:DNA substrate and b-thujaplicinol, our current structural
results are consistent with a mechanism of inhibition in which
b-thujaplicinol forms a stable inhibitory complex with protein
and substrate that directly prevents the attacking water and
the scissile phosphate from being properly positioned for catal-
ysis. These studies provide a detailed visualization of a metal-
chelating inhibitor at the active site of RNH and could help the
development of therapeutic agents that bind to the RNH active
site, blocking viral replication.
Our biochemical results agree with previously published
data (Budihas et al., 2005) that b-thujaplicinol displays noncom-
petitive inhibitory kinetics. We propose that the nucleic acid
Figure 7. Comparison of Substrate and Inhibitor Binding
The RNH active sites of human Ca2+-RNase H1 from a structure of a complex
with RNA:DNA (magenta protein carbon atoms and cyan nucleic acid carbon
atoms, Ca2+ atoms magenta) (Nowotny et al., 2007) and HIV-1 RT from the
complex with b-thujaplicinol are superimposed. The RTMn2+ atoms are shown
in black and labeled A and B as in Figure 5. The separation distance between
each Mn2+ atom and the corresponding Ca2+ atom is 0.6 A˚ for Mn2+ atom A
and 1 A˚ for Mn2+ atom B. Some of the RT RNH active site side-chains are
shown with yellow carbon atoms and are labeled to indicate the quality of
the superposition (RT residue = corresponding human RNase H1 residue:
Asp443 = Asp145; Glu478 = Glu186; Asp498 = Asp210; Asp549 = Asp274;
His539 = His264). The nucleophile (red) is a water molecule in the human
Ca2+-RNaseH1/RNA:DNA structure. This superposition suggests that b-thuja-
plicinol (translucent gray and pink atoms) occupies the position that would nor-
mally be occupied by the scissile phosphate of the RNA template strand and
the attacking nucleophilic water molecule.Structure 17, 1625–1substrate is able to bind the E$I complex and form a stable E$S$I
complex. The formation of this ternary complex results in
noncompetitive kinetics in the steady state. Furthermore, we
propose that the substrate binding enhances inhibitor binding
either by forming direct favorable interactions with the inhibitor
or by sterically blocking inhibitor dissociation. Our modeling
Figure 8. Modeling Inhibitor-Substrate Interactions
Shown is a superposition of the active sites of two crystal structures: (1) RT/
b-thujaplicinol (same vantage point as in Figure 7); and (2) RT/RNA:DNA with
no bound inhibitor (magenta protein carbon atoms and cyan nucleic acid
carbon atoms) (Sarafianos et al., 2001). The RT Mn2+ atoms are shown in
gray and labeled A and B as in Figures 5 and 7. Inset: Close-up view of the
RNH active site rotated 45 as indicated to show the distance between the
inhibitor and the scissile phosphate of the substrate. Some of the RT/b-thuja-
plicinol active site side-chains are shown with yellow carbon atoms to indicate
the quality of the superposition. The polypurine tract of the RNA:DNA substrate
positions the scissile phosphate about 4 A˚ away from the RNH active site,
providing a space for b-thujaplicinol to make the same interactions with RT
that are present in our current structures. According to the superposition,
the positively charged tropolone ring of b-thujaplicinol would be positioned
to interact favorably with the scissile phosphate of the substrate (dashed lines).635, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1631
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lays over the top of the inhibitor while it is bound at the active site.
This model would predict that a pre-formed E$S complex would
be resistant to inhibition by an active site directed inhibitor,
consistent with recently published pre-steady-state inhibition
studies and polymerase dependent RNase H inhibitions studies
(Beilhartz et al., 2009). We cannot exclude the possibility that
b-thujaplicinol has two binding modes, one at higher affinity
that gives rise to noncompetitive kinetics, and one at the RNH
active site that is far weaker and does not affect the biochemical
kinetics that we observe. However, there is no evidence to date
that suggests multiple binding modes.
Designing an RNHI that can be used as an anti-AIDS drug
presents a challenge, both because the structure of the active
site of HIV-1 RNase H is very flat and because it is quite similar
to the active site of human RNase H (Figure 7). A therapeutically
useful RNHI will have to inhibit HIV RNase H activity potently
and specifically, without inhibiting the corresponding cellular
enzymes. The RNHI b-thujaplicinol inhibits HIV-1 RT by binding
to catalytically essential residues of the RNH active site and
chelating the essential metal ions. The IC50 of b-thujaplicinol
for the RNH of HIV-1 RT is 30-fold greater than that of human
RNase H1, almost 300-fold greater than that of E. coli RNase H
(Budihas et al., 2005), and over 10-fold greater than that of
HIV-1 integrase (data not shown). The fact that compounds
have been developed that interact with the active site of HIV-1
integrase with a much greater specificity suggests that addi-
tional improvements can be made in the development of RNH
inhibitors. The current structures should provide guidance that
can be used to introduce additional substituents onto b-thujapli-
cinol that could enhance discrimination between the retroviral
and the human enzymes.
EXPERIMENTAL PROCEDURES
Expression and Purification of HIV-1 RT for Structural Studies
An HIV-1 RT variant (designated RT69A) was used for X-ray diffraction studies.
In this variant, the p66 subunit containedmutations F160S andC280S andwas
truncated at residue 555 (Bauman et al., 2008). The p51 subunit contained
a HRV14 3C protease cleavable N-terminal hexahistidine tag and a C280S
mutation and was truncated at residue 428. RT69A was expressed and puri-
fied as described elsewhere (Bauman et al., 2008). Briefly, 1 mM IPTG was
used to induce BL21-CodonPlus-RIL (Stratagene) containing a plasmid en-
coding both subunits of RT69A at an OD600 of 0.9, and the culture was incu-
bated for 3 hr at 37C. The cells were pelleted and lysed by sonication. Protein
was purified by Ni-NTA according to the manufacturer’s recommendations
(QIAGEN) with the following modifications: each buffer contained 600 mM
NaCl, no lysozyme was added, and a 1.2 M NaCl wash was added. Eluted
protein was incubated with HRV14 3C protease overnight at 4C. A Mono Q
purification step was performed as described elsewhere (Clark, Jr., et al.,
1995). The RT69A protein was concentrated to 20 mg/ml1 in ‘‘RT storage
buffer’’ (10 mM Tris [pH 8.0] and 75 mM NaCl) and was stored at 80C.
Expression and Purification of HIV-1 RT for Biochemical Studies
Full-length wild-type HIV-1 RT p66, from strain BH10, was expressed in E. coli
BL21(DE3) andwas inducedwith 0.1 mM IPTG overnight at 25C (Brodsky and
Cronin, 2006). A cell pellet corresponding to 3 L of culture was resuspended in
30 mM Tris (pH 8.0), 10% glycerol, 250 mMNaCl, 1 mM EDTA, and 2 mM DTT
and was disrupted by microfluidization (Microfluidics, model M-110 Y). After
adjustment of the NaCl concentration to 1 M, the lysate was sonicated for
1 min 45 s. The lysate was clarified by ultracentrifugation (Beckman L8-M) at
125,171 3 g for 45 min and was dialyzed overnight against buffer A (25 mM
Tris (pH 8.0) and 2 mM DTT). The dialyzed RT was loaded onto a 110 ml1632 Structure 17, 1625–1635, December 9, 2009 ª2009 Elsevier Ltheparin-Sepharose CL-6B column (GE Healthcare) equilibrated in buffer A.
The protein was loaded overnight at a flow rate of 0.5 ml/min. The column
was washed, and RT was eluted with a linear gradient using 8 column volumes
of buffer A plus 0.8 M NaCl. Fractions were pooled according to SDS-PAGE
and biochemical assays. At this point, the RT had been converted to the
p66/p51 heterodimer by E. coli proteases. The heparin pool was dialyzed over-
night in buffer B (25mMHEPES [pH 7.0], 25mMNaCl, and 2mMDTT) andwas
loaded onto a 20 ml Source 15Q column connected in series to a 10 ml SP-
sepharose HP column (GE Healthcare) equilibrated in buffer B. HIV-1 RT
was eluted from SP sepharose with a 30 column volume gradient of buffer B
plus 0.5 M NaCl. SP fractions were pooled according to SDS-PAGE and
were dialyzed overnight against a buffer containing 50 mM Tris (pH 8.0) and
2mMDTT. Dialyzed SP fractions were concentrated and loaded onto a HiPrep
26/60 Sephacryl S-200 HR column (GE Healthcare). Fractions were pooled,
aliquoted, and stored at 80C.
Expression and Purification of Isolated RNH Domain
The isolated RNH domain (amino acids 427–560, HIV-1 BH10) was cloned into
a modified pET vector that coded for an N-terminal 6x-His tag followed by
a TEV protease recognition sequence. Expression was induced by 0.1 M
IPTG in E. coli BL21(DE3) cells at 16C overnight (Brodsky and Cronin,
2006), and the isolated RNH was purified as follows: A cell pellet correspond-
ing to 2 L of culture was suspended in buffer C (25 mM Tris–HCl [pH 8.0],
25 mM NaCl, 20 mM imidazole, and 0.25 mM TCEP) and was disrupted and
clarified as described above for the purification of RT for Biochemical assays.
The supernatant fraction was collected and loaded onto a 5ml ProBond nickel
affinity column (Invitrogen) equilibrated in Buffer C. The column was washed
with 30 column volumes of buffer C plus 1 M NaCl, followed by a second
30 column volume wash with buffer C. The isolated RNH domain was step-
eluted with 30 column volumes of buffer D (25 mM Tris-HCl [pH 8.0], 25 mM
NaCl, 400 mM imidazole, and 0.25 mM TCEP). Eluted isolated RNH domain
was dialyzed with recombinant TEV protease at room temperature overnight
against buffer containing 25 mM Tris-HCl (pH 8.0), 50 mM NaCl, 20 mM imid-
azole, and 0.25 mM TCEP. The dialyzed solution containing the isolated RNH
domain was further incubated the following morning in a 37C water bath for
8 hr. The solution containing the cleaved isolated RNH domain was adjusted
to 0.5 M NaCl, and uncleaved material was removed with a second passage
over a 5 ml nickel affinity column. The isolated RNH domain was collected in
the flow through, concentrated, and loaded to a gel filtration (HiLoad 26/60
Superdex-75) column equilibrated in 25 mM Tris-HCl (pH 7.6), 50 mM NaCl,
and 0.25 mM TCEP. The isolated RNH domain was eluted in two peaks corre-
sponding to monomeric and dimeric forms of the protein. Monomer fractions
were pooled, concentrated to 20 mg/ml, and stored at 80C.
Isolated RNase H domain used for kinetic experiments contained a
C-terminal histidine tag to facilitate enzymatic activity. This protein was
made as described elsewhere (Hang et al., 2004).
Crystallization and Data Collection
HIV-1 RT was cocrystallized with b-thujaplicinol by vapor diffusion in micro-
seeded hanging drops containing 1.3 ml each of 20 mg/ml1 protein in RT
storage buffer and reservoir solution (50 mM Bicine [pH 8.2], 45 mM ammo-
nium sulfate, 15 mM manganese sulfate, 10 mM spermine, 5 mM taurine,
2% [v/v] PEG 400, and 10% [w/w] PEG 8000) at 4C. Crystals were transferred
to a stabilization solution containing 14% (w/w) PEG 8000 in the above
mother liquor and 5% PEG 200 instead of PEG 400. In the presence of 0.86
mM b-thujaplicinol, the PEG 200 concentration was raised stepwise in 5%
increments by solution replacement at 1–3-min intervals per step to a final
concentration of 26% (w/v) PEG 200. The crystals were subsequently flash-
cooled and stored in liquid N2. X-ray data were collected at 100 K and a wave-
length of 1.1 A˚ at the National Synchrotron Light Source at Brookhaven
National Laboratories, Beamline X25. The data were processed using
DENZO/SCALEPACK (Otwinowski and Minor, 2001; Otwinowski and Minor,
1997).
Crystals of the isolated RNH domain were grown by vapor diffusion in
hanging drops containing 1.0 ml each of 21.6 mg ml1 protein (in 25 mM Tris
[pH 7.6], 50 mM NaCl, and 0.25 mM TCEP) and well solution (200 mM formate
[pH 7.0], 10% [w/v] PEG 3350, and 10mMMnCl2) at 21
C. Drops were soaked
with 0.04 ml of 200 mM b-thujaplicinol in DMSO for 4.5 hr. The crystal wasd All rights reserved
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erol followed by flash-cooling and storage in liquid N2. Data were collected on
a RuH2R generator with a MAR345 detector. The data were integrated and
scaled using DENZO/SCALEPACK (Otwinowski and Minor, 1997, 2001).
Structure Determination and Refinement
Phases for the HIV-1 RT/b-thujaplicinol data were determined by molecular
replacement with the CCP4 program PHASER (Read, 2001), using an unli-
ganded RT structure (PDB accession number 1DLO) Hsiou et al., 1996) as
an initial search model. Stepwise model building and refinement were con-
ducted using the ‘‘O’’ graphics package (Jones et al., 1991), the Coot graphics
package (version 0.3.1) (Emsley and Cowtan, 2004), and CNS 1.1 (Bru¨nger
et al., 1998) with a bulk solvent correction.Water molecules were built inmanu-
ally. The geometry of the inhibitor and refinement of the RNH active site were
improved by energy minimization using the Impact and PrimeX facilities of the
Schro¨dinger software package (Schro¨dinger, LLC).
The structure of the isolated RNH domain was solved by molecular replace-
ment with CCP4 PHASER (Read, 2001) using an unliganded isolated RNH
domain structure (PDB accession number 1HRH) (Davies et al., 1991) as
a search model. The model was refined using CCP4 Refmac (Murshudov
et al., 1997), with ligand restraints generated by Sketcher in CCP4. Root
mean square differences between corresponding atoms of the isolated RNH
domain and RT were calculated in CNS.
Enzymatic Activity Assays
The RNH activity of HIV-1 RT was determined essentially as described else-
where (Parniak et al., 2003) with minor modifications. Briefly, 1 nM HIV-1 RT
was incubated with 150 nM 18-mer RNA:DNA hybrid FRET substrate in 13
FRET buffer (50 mM Tris [pH 8.0], 60 mM KCl, 5 mM MgCl2, and 0.02%
Tween-20). The enzyme-mediated increase in fluorescence was monitored
at 520 nm using a Tecan Safire plate reader. Product formation was deter-
mined at various concentrations of b-thujaplicinol under initial velocity condi-
tions. The progress curves were fit to Equation 1, solving for kobs, vi, and vs
using GraphPad Prism (GraphPad Software Inc.). Estimates of Ki
app were
generated by (1) plotting kobs versus b-thujaplicinol concentration and fitting
the data to Equation 2 and (2) plotting vs versus b-thujaplicinol and fitting to
the standard hyperbolic IC50 equation (Equation 3).

P

= nst +
ni  ns
kobs

1 expð  kobstÞ

; (1)
where vi is initial velocity, vs is steady state velocity, and kobs is the rate
constant for the conversion from the initial rate to the steady state rate.
kobs = k4

1+
½I
Kappi

; (2)
where k4 is the dissociation rate constant, kobs is determined from Equation 1,
and [I] is the inhibitor concentration.
ni
n0
=
1
1+ ð½I=IC50Þ: (3)
The enzymatic activity of the isolated RNase H domain was determined as
described for HIV-1 RT with the following changes. The enzyme concentration
used was 500 mM, the 18-mer FRET substrate concentration was varied
between 1 and 20 mM (Km= 7 mM), and the reactionwas run in buffer containing
50 mM Tris (pH 7.5), 20 mM KCl, 0.02% Tween-20, and 8 mM MnCl2.
Direct Binding Assay Using Intrinsic Protein Fluorescence
b-thujaplicinol binding to HIV-1 RT was detected by monitoring the quenching
of intrinsic tryptophan fluorescence as a function of inhibitor concentration.
The fluorescence emission spectra were monitored using a Perkin Elmer
LS-50B fluorimeter by exciting the protein (0.8 uM in 1 ml) in 13 FRET buffer
minus the Tween-20+/ double-stranded 18-mer RNA substrate analog, at
295 nm. The dsRNA used is identical to the hybrid substrate used for the
activity assay except that it contains only RNA. HIV-1 RT is unable to cleave
this dsRNA analog in the presence of MgCl2 (data not shown). Multiple small
aliquots of b-thujaplicinol in 10% (v/v) DMSO (25 ml total per experiment)
were titrated into the protein sample, and the quench in protein fluorescenceStructure 17, 1625–1was determined. Multiple scans were performed at various incubation times
to ensure protein stability and equilibrium conditions during titrations. Protein
fluorescence measurements in the presence of inhibitor were corrected for
protein dilution. DMSO titrations showed no quenching of the fluorescence
signal at concentrations achieved in the b-thujaplicinol titrations (<1%). Inner
filter effects were corrected for by performing b-thujaplicinol titrations into
free N-acetyl-L-tryptophanamide (Cogan et al., 1976). The quench observed
upon titration into free N-acetyl-L-tryptophanamide was subtracted from the
quench observed upon titration into HIV-1 RT. The IC50 for binding was esti-
mated by plotting the corrected relative fluorescence value as a function of
inhibitor concentration.
Direct Binding Assay Using Surface Plasmon Resonance
Small molecule binding studies were performed using a Biacore 3000 instru-
ment (GE Healthcare) at 20C in a 60 mM KCl, 50 mM Tris-HCl (pH 8.0),
8mMMgCl2, 0.005%P20 detergent, 2.0mMDTT, and 1% (v/v) DMSO running
buffer. Samples of the isolated RNH domain or full-length HIV-1 RT were
immobilized on a Biacore CM5 chip by standard EDC/NHS amine coupling
chemistry, using a 0.4 mM solution of the protein, in 10 mM sodium acetate
buffer (pH 6.0) at 25C. Immobilization was performed in the presence of
a saturating concentration of b-thujaplicinol to minimize perturbation of
the active site upon coupling to the chip surface. In a typical experiment,
compound injections were made at a flow rate of 50 ml per minute using the
Biacore ‘‘kinject’’ mode, which is designed to minimize sample dispersion
during injection (GE Healthcare). Compound injections were made in duplicate
using a two-fold dilution series from a 100 mM starting concentration. Data
analysis was performed using the Scrubber2 software package (BioLogic
Software). Compound injections were referenced to both a blank surface
and by a buffer blank. Processed data were fit to an equilibrium model for
single set of binding sites to obtain the observed equilibrium dissociation
constant KD. SPR-based b-thujaplicinol binding studies could not be per-
formed in the presence of dsRNA substrate analog. To ensure continuous
exposure to the enzyme, the substrate analog must be present in the running
buffer and compound samples. This would have required impractical quanti-
ties of substrate analog. Binding studies done in the absence of magnesium
were performed identically except that MgCl2 was omitted from the buffer
and 0.1 mM EDTA was added. Control experiments were run immediately
before and after the magnesium omit studies to verify active protein on the
chip.
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